// App-Quantinova.ai

TCT-624 : A prospective multicenter randomized post-market trial evaluating a novel Cobalt Chrome Rapamycin Drug Eluting Stent: Subgroup Analysis of the TARGET All Comers Trial

Researchers

Presenter

  • Alexandra Lansky

Principal Investigators

  • Bo Xu

  • Henning Kelbaek

  • Niels van Royen

  • Ming Zheng

  • Laure Artus-Jacenko

  • Paul Knaapen

  • Ton Slagboom

  • Georgios Vlachojannis

  • Karin Arkenbout

  • Lene Holmvang

  • Luc Janssens

  • Andrzej Ochala

  • Salvatore Brugaletta

  • Oliver Bruder

  • Sergio Berti

  • Emanuele Barbato

  • Gabor Toth

  • Luc Maillard

  • Christian Valina

  • Piotr Buszman

  • Tom Johnson

  • Holger Thiele

  • Andreas Baumbach

Medical Centers

  • Universitäts-Herzzentrum Bad Krozingen, Bad Krozingen, Germany

  • Zealand University Hospital, Roskilde, Denmark, Roskilde, Denmark

  • Maasstad Hospital, Rotterdam, Netherlands

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China, Beijing, Beijing, China

  • Cardiovascular Research Center Aalst OLV Hospital, Aalst, Belgium

  • Yale School of Medicine, New Haven, Connecticut, United States

  • Radboud University, Nijmegen, Netherlands

  • Department of Cardiology, Tergooi Hospital, Blaricum, Netherlands

  • Rigshospitalet, Copenhagen, Denmark

  • Heart Center Leipzig, University Hospital, Leipzig, Germany

  • Center of Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland

  • University Hospitals, Leuven, Belgium

  • VU University Medical Center, Amsterdam, Netherlands

  • Barts Heart Centre, London, United Kingdom

  • University of Graz, Graz, Austria

  • Contilla, Cologne, Germany

  • OLVG, Amsterdam, Netherlands

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Fondazione Toscana G. Monasterio, Massa, Massa and Carrara, Italy

  • Bristol Heart Institute, Bristol, United Kingdom

  • Lambe Institute for Translational Medicine and CURAM, National University of Ireland Galway, Galway, Ireland

  • GCS ES Axium Rambot, Aix en Provence, France

  • Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland

Locations

  • Germany

  • China

  • Netherlands

  • Italy

  • France

  • Denmark

  • Belgium

  • Poland

  • United Kingdom

  • United States

  • Austria

  • Spain

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

Biomarkers

  • N/A

Drug/Treatment

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved